Table 2.

Incidence and Pathology of Tumors Produced by Orthotopic Injection of MYU-3L and Transfected Cells

Cells*	Tumor incidence†	Time blood first detected in urine, range (days)	Latent period, range (days)	Duration of experiment, range (days)	Incidence of metastasis‡
Controls and cells with less than three-fold induction of S100A4 mRNA
MYU-3L (parent line)	15 /15	20 (14–29)	22 (14–34)	42 (31–70)	0 /15
MYU-P§	9 /10	11 (5–22)	13 (9–18)	41 (28–58)	0 /9
MYU-plasmid¶	12 /12	25 (19–33)	23 (20–25)	43 (36–49)	0 /12
MYU-C6	8 /8	ND∥	18 (11–24)	49 (39–57)	0 /8
MYU-C2	6 /6	17 (17–18)	19 (15–24)	36 (28–47)	0 /6
Totals	50 /51	16 (5–33)	20 (9–34)	42 (28–70)	0 /50
Cells with at least 4-fold induction of S100A4 mRNA:
MYU-C7	8 /8	25 (19–33)	22 (15–25)	44 (28–59)	2 /8
MYU-C14	9 /9	25 (12–35)	17 (12–22)	39 (31–51)	2 /9
Totals	17 /17	25 (12–35)	19 (12–25)	41 (28–59)	4 /17**

*One to 2 × 10⁶ cells injected into the bladder wall.

^†No. of animals with tumors/no. of animals injected.

^‡No. of animals with metastases/no. of animals with tumors.

^§MYU-3L cells cultured from a nonmetastatic primary tumor and reinjected into a further group of animals.

^¶MYU-3L cells transfected with pSV2neo plasmid vector alone.

^∥ND, not determined.

**Significantly more metastases than controls and cells with less than three-fold induction of S100A4 mRNA (P < 0.05; Fisher’s exact test).